“Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

“Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”

Published:2024-08 Issue: Volume:76 Page:103742
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Conte Pierfranco,Ciruelos Eva,Curigliano Giuseppe,De Laurentiis Michelino,Del Mastro Lucia,Gennari Alessandra,Llombart Antonio,Martìn Miguel,Poggio Francesca^ORCID,Prat Aleix,Puglisi Fabio,Saura Cristina

Funder

Seagen

Publisher

Elsevier BV

Reference24 articles.

1. https://ecis.jrc.ec.europa.eu/pdf/Breast_cancer_2022-Oct_2023.pdf [n.d].

2. How we treat patients with metastatic HER2-positive breast cancer;Nader-Marta;ESMO Open,2022

3. Current and future management of HER2-positive metastatic breast cancer;Martínez-Sáez;JCO Oncol. Pract.,2021

4. Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: data from the GIM14/BIOMETA study;Di Maio;Breast. Edinb. Scotl.,2023

5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP